Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Lilly Takes First Jab in Obesity Drug Showdown
02:09pm, Thursday, 09'th Nov 2023
Eli Lilly says its obesity drug's list price is about 20% lower than Novo's Wegovy.
Eli Lilly's Big Win In The Obesity Space Just Got Bigger
01:43pm, Thursday, 09'th Nov 2023
Eli Lilly received FDA approval to sell tirzepatide for obesity treatment, expanding its market beyond diabetes. Shares of Eli Lilly jumped 3.2% on the news, resulting in a $17.3 billion increase in s
Eli Lilly Has Yet Another Ozempic Killer in the Works. Is It a Screaming Buy?
09:35am, Thursday, 09'th Nov 2023
Eli Lilly is eager to steal market share from Novo Nordisk's drug Ozempic. Creating medicines that don't have certain side effects is one strategy.
Eli Lilly: still seeking UK approval on pen for weight-loss drug
08:38am, Thursday, 09'th Nov 2023
Eli Lilly on Thursday said it has not yet gained approval in Britain for the injection pen it plans to use for its Mounjaro drug against obesity and diabetes, adding to uncertainty over timing of the
'Wonder' diabetes drug Mounjaro approved in the UK
07:48am, Thursday, 09'th Nov 2023
Diabetes blockbuster Mounjaro has been approved for use by the UK drugs agency MHRA after two clinical trials showed patients taking shed between 16%-22% of their weight in little more than a year. De
Earnings Estimates Come Under Pressure
07:32pm, Wednesday, 08'th Nov 2023
While Q3 results have been better than expected, there is a notable acceleration in negative estimate revisions over the last few weeks, contrasting the largely favorable revisions trend of the preced
Earnings Estimates Come Under Pressure
07:32pm, Wednesday, 08'th Nov 2023
While Q3 results have been better than expected, there is a notable acceleration in negative estimate revisions over the last few weeks, contrasting the largely favorable revisions trend of the preced
BofA'S Meacham on what's next for Eli Lilly after FDA approves obesity drug
06:33pm, Wednesday, 08'th Nov 2023
Geoff Meacham, Bank of America, joins 'Fast Money' to talk the FDA's approval of Eli Lilly's obesity drug.
FDA approves Eli Lilly's Mounjaro for weight loss
06:31pm, Wednesday, 08'th Nov 2023
The Food and Drug Administration has approved Eli Lilly and Company's (LLY) Mounjaro, under the name Zepbound, for the treatment of obesity. Previously, Novo Nordisk's (NVO) Wegovy and Ozempic were th
FDA approval of Eli Lilly's Zepbound is a win for patients as Ozempic competitors boom
06:20pm, Wednesday, 08'th Nov 2023
Pharmaceutical companies are now racing to develop anti-obesity drugs, and experts say that could drive supply up, and price down. The U.S. Food and Drug Administration (FDA) announced Wednesday that
Eli Lilly Shares Hit All-Time High After FDA Approves Drug for Weight-Loss Treatment
06:10pm, Wednesday, 08'th Nov 2023
Eli Lilly (LLY) shares hit an all-time high Wednesday after the Food and Drug Administration (FDA) approved the drug maker's Zepbound injection to treat people who are obese or are overweight and also
Eli Lilly's Zepbound has a strong shot of being the biggest drug of all time: Guggenheim's Fernandez
03:41pm, Wednesday, 08'th Nov 2023
Guggenheim analyst Seamus Fernandez joins 'Power Lunch' to discuss Eli Lilly's latest drug to get FDA approval, whether it'll become the biggest-selling drug of all time, and who will be on the hook i
FDA Approves Diabetes Drug Mounjaro For Weight Loss Under Brand Name Zepbound
03:38pm, Wednesday, 08'th Nov 2023
Eli Lilly's Zepbound helped users lose up to 22.5% of their weight in clinical trials.
UK's MHRA authorises Eli Lilly's Mounjaro
03:22pm, Wednesday, 08'th Nov 2023
Britain's health regulator on Wednesday authorised Eli Lilly's diabetes drug Mounjaro for weight management and weight loss in the UK.
What to know about Eli Lilly's new obesity drug
03:04pm, Wednesday, 08'th Nov 2023
The U.S. Food and Drug Administration approved Eli Lilly's keenly-awaited obesity treatment on Wednesday, introducing a powerful rival to Novo Nordisk's popular weight-loss therapy Wegovy.
